Necromass in forests of Madre de Dios, Peru: a comparison between terra firme and lowland forests

Stocks of dead wood or necromass represent an important portion of biomass and nutrients in tropical forests. The objectives of this study were: 1) to evaluate and compare the necromass of "terra firme" and lowlands forests, (2) to study the relationship between necromass, above-ground biomass and wood density, and (3) to estimate the necromass of the department of Madre de Dios, Peru. Stocks of necromass and above-ground biomass were estimated at three different locations using permanent plots and line intercept transects. The average volume of necromass for the three sites was 72.9 m3 ha-1 with an average weight varying between 24.8 and 30.7 Mg ha-1, depending on the estimations of dead wood density used for the calculations. Terra firme forests had significantly higher stocks of necromass than lowland forests. The amount of necromass was 11% of the total above-ground biomass in Madre de Dios forests. The total stock of carbon stored in dead wood for the entire department of Madre de Dios was estimated to be approximately 100 mega tonnes of carbon. This is ten times more than the annual fossil fuel emissions of Peru between 2000 and 2008. The substantial stocks of necromass emphasize the importance of these types of field studies, considering that this component of tropical forest carbon cannot be detected using other methods such as satellite remote sensing

Necromass in forests of Madre de Dios, Peru: A comparison between terra firme and lowland forests

This is the final version of the article. Available from Universidad Nacional Mayor de San Marcos, Facultad de Ciencias Biológicas via the DOI in this record.Stocks of dead wood or necromass represent an important portion of biomass and nutrients in tropical forests. The objectives of this study were: 1) to evaluate and compare the necromass of “terra firme” and lowlands forests, (2) to study the relationship between necromass, above-ground biomass and wood density, and (3) to estimate the necromass of the department of Madre de Dios, Peru. Stocks of necromass and above-ground biomass were estimated at three different locations using permanent plots and line intercept transects. The average volume of necromass for the three sites was 72.9 m3 ha-1 with an average weight varying between 24.8 and 30.7 Mg ha-1, depending on the estimations of dead wood density used for the calculations. Terra firme forests had significantly higher stocks of necromass than lowland forests. The amount of necromass was 11% of the total above-ground biomass in Madre de Dios forests. The total stock of carbon stored in dead wood for the entire department of Madre de Dios was estimated to be approximately 100 mega tonnes of carbon. This is ten times more than the annual fossil fuel emissions of Peru between 2000 and 2008. The substantial stocks of necromass emphasize the importance of these types of field studies, considering that this component of tropical forest carbon cannot be detected using other methods such as satellite remote sensing

A Mycobacterium leprae Hsp65 Mutant as a Candidate for Mitigating Lupus Aggravation in Mice

Hsp60 is an abundant and highly conserved family of intracellular molecules. Increased levels of this family of proteins have been observed in the extracellular compartment in chronic inflammation. Administration of M. leprae Hsp65 [WT] in [NZBxNZW]F1 mice accelerates the Systemic Lupus Erythematosus [SLE] progression whereas the point mutated K409A Hsp65 protein delays the disease. Here, the biological effects of M. leprae Hsp65 Leader pep and K409A pep synthetic peptides, which cover residues 352–371, are presented. Peptides had immunomodulatory effects similar to that observed with their respective proteins on survival and the combined administration of K409A+Leader pep or K409A pep+WT showed that the mutant forms were able to inhibit the deleterious effect of WT on mortality, indicating the neutralizing potential of the mutant molecules in SLE progression. Molecular modeling showed that replacing Lysine by Alanine affects the electrostatic potential of the 352–371 region. The number of interactions observed for WT is much higher than for Hsp65 K409A and mouse Hsp60. The immunomodulatory effects of the point-mutated protein and peptide occurred regardless of the catalytic activity. These findings may be related to the lack of effect on survival when F1 mice were inoculated with Hsp60 or K409A pep. Our findings indicate the use of point-mutated Hsp65 molecules, such as the K409A protein and its corresponding peptide, that may minimize or delay the onset of SLE, representing a new approach to the treatment of autoimmune diseases

2 nd Brazilian Consensus on Chagas Disease, 2015

Abstract Chagas disease is a neglected chronic condition with a high burden of morbidity and mortality. It has considerable psychological, social, and economic impacts. The disease represents a significant public health issue in Brazil, with different regional patterns. This document presents the evidence that resulted in the Brazilian Consensus on Chagas Disease. The objective was to review and standardize strategies for diagnosis, treatment, prevention, and control of Chagas disease in the country, based on the available scientific evidence. The consensus is based on the articulation and strategic contribution of renowned Brazilian experts with knowledge and experience on various aspects of the disease. It is the result of a close collaboration between the Brazilian Society of Tropical Medicine and the Ministry of Health. It is hoped that this document will strengthen the development of integrated actions against Chagas disease in the country, focusing on epidemiology, management, comprehensive care (including families and communities), communication, information, education, and research

Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial

Aims  The third Universal Definition of Myocardial Infarction (MI) Task Force classified MIs into five types: Type 1, spontaneous; Type 2, related to oxygen supply/demand imbalance; Type 3, fatal without ascertainment of cardiac biomarkers; Type 4, related to percutaneous coronary intervention; and Type 5, related to coronary artery bypass surgery. Low-density lipoprotein cholesterol (LDL-C) reduction with statins and proprotein convertase subtilisin–kexin Type 9 (PCSK9) inhibitors reduces risk of MI, but less is known about effects on types of MI. ODYSSEY OUTCOMES compared the PCSK9 inhibitor alirocumab with placebo in 18 924 patients with recent acute coronary syndrome (ACS) and elevated LDL-C (≥1.8 mmol/L) despite intensive statin therapy. In a pre-specified analysis, we assessed the effects of alirocumab on types of MI. Methods and results  Median follow-up was 2.8 years. Myocardial infarction types were prospectively adjudicated and classified. Of 1860 total MIs, 1223 (65.8%) were adjudicated as Type 1, 386 (20.8%) as Type 2, and 244 (13.1%) as Type 4. Few events were Type 3 (n = 2) or Type 5 (n = 5). Alirocumab reduced first MIs [hazard ratio (HR) 0.85, 95% confidence interval (CI) 0.77–0.95; P = 0.003], with reductions in both Type 1 (HR 0.87, 95% CI 0.77–0.99; P = 0.032) and Type 2 (0.77, 0.61–0.97; P = 0.025), but not Type 4 MI. Conclusion  After ACS, alirocumab added to intensive statin therapy favourably impacted on Type 1 and 2 MIs. The data indicate for the first time that a lipid-lowering therapy can attenuate the risk of Type 2 MI. Low-density lipoprotein cholesterol reduction below levels achievable with statins is an effective preventive strategy for both MI types.For complete list of authors see http://dx.doi.org/10.1093/eurheartj/ehz299</p